A Phase 2 Indication Identification Study of LY2523355 in Patients With Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Inclusion Criteria:

- Diagnosis of ovarian, non-small cell lung, prostate, colorectal, gastroesophageal
cancer, or squamous cell cancer of the head and neck

- Have measurable disease defined by Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1 guidelines (except prostate cancer patients)

- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

- Are willing to follow study procedures for the duration of the study

- Are willing to use an approved contraceptive method during treatment and for 3 months
after discontinuation of study treatment

Exclusion Criteria:

- Have a serious preexisting medical condition that would preclude participation in the
study

- Are pregnant or lactating

- Have received treatment within 28 days of first dose of LY2523355 with a drug that
has not received regulatory approval for any indication

- Have symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases

- Have a second active primary malignancy or a history of a second malignancy requiring
cytotoxic therapy

- Have QTc interval greater than 470 msec or intraventricular conduction delay (IVCD)
with QRS greater than 120 msec on screening electrocardiogram (ECG)

- Have active symptomatic fungal, bacterial, and/or known viral infection including
active human immunodeficiency virus (HIV) or viral (A, B, C) hepatitis

- Patients with pneumonia, evidence of obstructive pneumonitis, other respiratory
infections, or infection from other sources are to be excluded